Advaxis (NASDAQ:ADXS) – Equities researchers at Cantor Fitzgerald increased their FY2018 earnings per share (EPS) estimates for Advaxis in a research report issued on Tuesday, March 13th, according to Zacks Investment Research. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will post earnings per share of ($1.91) for the year, up from their prior forecast of ($2.28). Cantor Fitzgerald has a “Overweight” rating and a $5.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Advaxis’ FY2019 earnings at ($1.96) EPS.
A number of other research analysts have also recently issued reports on the stock. HC Wainwright set a $6.00 price target on shares of Advaxis and gave the stock a “buy” rating in a report on Wednesday, March 14th. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
Shares of NASDAQ ADXS traded down $0.06 during midday trading on Friday, reaching $1.69. The company had a trading volume of 401,439 shares, compared to its average volume of 1,058,601. The stock has a market cap of $91.55, a P/E ratio of -0.73 and a beta of 1.19. Advaxis has a 1 year low of $1.51 and a 1 year high of $9.55.
Advaxis (NASDAQ:ADXS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.06. The business had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $3.03 million. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%.
Several institutional investors have recently modified their holdings of ADXS. Renaissance Technologies LLC purchased a new position in shares of Advaxis during the fourth quarter worth $1,398,000. Deutsche Bank AG raised its holdings in shares of Advaxis by 1,200.1% during the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock worth $1,326,000 after purchasing an additional 431,379 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of Advaxis by 16,465.9% during the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock worth $1,230,000 after purchasing an additional 430,583 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock worth $11,572,000 after purchasing an additional 119,980 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC raised its holdings in shares of Advaxis by 117.1% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 70,000 shares during the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/fy2018-eps-estimates-for-advaxis-inc-lifted-by-cantor-fitzgerald-adxs.html.
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Get a free copy of the Zacks research report on Advaxis (ADXS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.